Pluri (PLUR) Asset Writedowns and Impairment (2017)
Pluri (PLUR) posted quarterly Asset Writedowns and Impairment of $850000.0 for Q3 2017.
Pluri (PLUR) Asset Writedowns and Impairment (2017) Analysis & Trends
Pluri (PLUR) has reported Asset Writedowns and Impairment for 1 consecutive years, with $850000.0 the latest figure, recorded in Q3 2017.
- In Q3 2017, Asset Writedowns and Impairment changed N/A year-over-year to $850000.0; the TTM figure through Jun 2018 stood at $850000.0 (changed N/A YoY), while the FY2018 annual figure was $850000.0, up 10.82% from the prior year.
- Asset Writedowns and Impairment was little changed at $850000.0 in Q3 2017 per PLUR's latest filing.
- Across five years, Asset Writedowns and Impairment topped out at $850000.0 in Q3 2017 and bottomed at $850000.0 in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 850,000.00 |
| Sep 30, 2017 | 850,000.00 |